ALDER BIOPHARMACEUTICALS INC's ticker is ALDR and the CUSIP is 014339105. A total of 141 filers reported holding ALDER BIOPHARMACEUTICALS INC in Q4 2017. The put-call ratio across all filers is 2.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $949,000 | +190.2% | 50,360 | +81.0% | 0.00% | – |
| Q2 2019 | $327,000 | -3.5% | 27,821 | +12.0% | 0.00% | – |
| Q1 2019 | $339,000 | +33.5% | 24,842 | 0.0% | 0.00% | – |
| Q4 2018 | $254,000 | -34.0% | 24,842 | +7.3% | 0.00% | – |
| Q3 2018 | $385,000 | +5.2% | 23,144 | 0.0% | 0.00% | – |
| Q2 2018 | $366,000 | +13.0% | 23,144 | -9.4% | 0.00% | – |
| Q1 2018 | $324,000 | +45.3% | 25,547 | +31.1% | 0.00% | – |
| Q4 2017 | $223,000 | -3.5% | 19,487 | +2.5% | 0.00% | – |
| Q3 2017 | $231,000 | +30.5% | 19,011 | +22.7% | 0.00% | – |
| Q2 2017 | $177,000 | -44.0% | 15,496 | +2.6% | 0.00% | – |
| Q1 2017 | $316,000 | -0.6% | 15,096 | -1.3% | 0.00% | – |
| Q4 2016 | $318,000 | -1.2% | 15,289 | +51.6% | 0.00% | – |
| Q3 2016 | $322,000 | +17.5% | 10,087 | -9.7% | 0.00% | – |
| Q2 2016 | $274,000 | +35.0% | 11,171 | +33.8% | 0.00% | – |
| Q1 2016 | $203,000 | +14.7% | 8,349 | +57.6% | 0.00% | – |
| Q4 2015 | $177,000 | +25.5% | 5,296 | +16.2% | 0.00% | – |
| Q3 2015 | $141,000 | -15.1% | 4,556 | +34.2% | 0.00% | – |
| Q2 2015 | $166,000 | +418.8% | 3,396 | +214.4% | 0.00% | – |
| Q1 2015 | $32,000 | – | 1,080 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 229,895 | $7,593,000 | 6.73% |
| Foresite Capital Management II, LLC | 419,997 | $13,873,000 | 4.65% |
| Cormorant Asset Management, LP | 757,475 | $25,019,000 | 2.99% |
| NEXTHERA CAPITAL LP | 60,000 | $1,982,000 | 2.81% |
| SENZAR ASSET MANAGEMENT, LLC | 557,170 | $18,403,325,000 | 2.05% |
| Parametrica Management Ltd | 9,360 | $309,000 | 2.04% |
| Partner Investment Management, L.P. | 36,756 | $1,214,000 | 1.99% |
| PFM Health Sciences, LP | 1,890,030 | $62,428,000 | 1.90% |
| PYRRHO CAPITAL MANAGEMENT, LP | 63,000 | $2,081,000 | 1.40% |
| BB BIOTECH AG | 1,510,150 | $49,880,000 | 1.40% |